LRP8 and Alzheimer disease: We examined the correlation between ApoER2 exon 19 inclusion and performance in the MWM in the all groups (AD, non‐AD, ASO‐C‐, and ASO‐21‐treated) (Fig 6D) or in the transgenic AD animals that were treated with ASO‐C or ASO‐21 separately (Fig 6E), and found that there was a significant correlation between the percent of ApoER2 mRNA with inclusion of exon 19 and the distance traveled to reach the hidden platform on day 3 of the MWM (Fig 6D and E).